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Abstract 
Early detection of Parkinson's disease (PD) is important which can enable early initiation of 
therapeutic interventions and management strategies. However, methods for early detection still 
remain an unmet clinical need in PD. In this study, we use the Patient Questionnaire (PQ) portion 
from the widely used Movement Disorder Society-Unified Parkinson's Disease Rating Scale 
(MDS-UPDRS) to develop prediction models that can classify early PD from healthy normal 
using machine learning techniques that are becoming popular in biomedicine: logistic regression, 
random forests, boosted trees and support vector machine (SVM). We carried out both subject-
wise and record-wise validation for evaluating the machine learning techniques. We observe that 
these techniques perform with high accuracy and high area under the ROC curve (both >95%) in 
classifying early PD and healthy normal. The logistic model demonstrated statistically significant 
fit to the data indicating its usefulness as a predictive model. It is inferred that these prediction 
models have the potential to aid clinicians in the diagnostic process by joining the items of a 
questionnaire through machine learning. 
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1. Introduction 
Parkinson's disease (PD) is a neurodegenerative disorder affecting millions of elderly people, 
significantly affecting their quality of lives [1]. PD is a complex disorder characterized by 
several motor and non-motor symptoms that worsen over time. In advanced stages of PD, 
clinical diagnosis is clear-cut. However, in the early stages, when the symptoms are often 
incomplete or subtle, the diagnosis becomes difficult and at times, the subject may remain 
undiagnosed. For instance, a large-scale epidemiological study on a European cohort showed that 
a significant proportion of previously undetected subjects, were diagnosed with PD, after 
screening them with a symptom questionnaire followed by physical examination and clinical 
intervention [2]. Tremor, the most common symptom in PD, may never manifest in some 
patients and the patient may show other relevant symptoms such as bradykinesia (slower and 
smaller handwriting, decreased arm swing and leg stride when walking, decreased facial 
expression, and decreased amplitude of voice) to begin with [1]. The difficulty in early detection 
of PD is a strong motivation for computer-based assessment tools/decision support tools/test 
instruments that can aid in the early diagnosis of PD. Timely detection, preferably at a stage 
earlier than currently possible, and subsequent intervention could be hugely beneficial in a way 
that the patient could have access to disease modifying therapy to slow down the course of PD 
progression. 
Machine learning provides seemingly immense opportunities to computer-aided classification 
and diagnosis that could reduce inevitable fallibilities and inherent diagnostic variabilities in 
healthcare, provide guidance (especially in a setting when expert physicians are not available), 
and speed up decision making. These models can aid in the early detection of PD and also for 
identifying subjects for clinical trials. Researchers have used a variety of data for solving the PD 
detection problem via machine learning techniques. [3-7] used speech data, [8] studied gait 
patterns, [9] carried out analysis on force tracking data, [10-12] performed analysis on single 
photon emission computed tomography (SPECT) scan data, and [13] used smell identification 
data to distinguish PD from healthy normal. [14] carried out assessment of PD state based on 
many weeks of movement data collected from sensors from 34 subjects who were in mild to 
severe PD. [15] describes about the collaboration between Michael J. Fox Foundation for PD 
Research and Intel Corporation, to develop a mobile application and an Internet of Things (IoT) 
platform to support large-scale studies of objective, continuously sampled sensory data from 
people with PD. [16] in their study, proposes an approach to evaluate the feasibility and 
compliance of using multiple wearable sensors to collect clinically relevant data, and to address 
the usability of these data for answering clinical research questions. [17] is a continuation of their 
previous study [16] where they complete their data collection process and show that it is feasible 
to deploy a technology platform consisting of consumer-grade wearable and mobile devices to 
capture large amounts of sensor data from many participants from a large and geographically 
diverse PD population. [18] presents an approach to analyze smartwatch data from 19 PD 
subjects and shows high performance in terms of detecting symptoms of tremor, bradykinesia, 
and dyskinesia. [19] showed that dual-wrist sensor fusion may enable robust gait quantification 
(aiding in capturing timing-based, gait abnormalities) in free-living environments. [20] provides 
a review which discusses promising wearable technology, addresses which parameters should be 
prioritized in such assessment strategies, and reports about studies that have already investigated 
daily life issues in PD using this new technology. [21] used imaging, genetics, clinical and 
demographic data to develop prediction models for PD. [22] developed predictions models for 
PD using genetic, non-motor and demographic data. [23] used motor, non-motor and imaging 
data from to develop prediction models for PD. [24] developed multi-task learning model for the 
prediction of PD progression, measured using baseline measurements of biologic specimen, 
clinical assessments and brain imaging. [25] explored the non-motor symptoms (NMS) and 
quality of life (QOL) in tremor dominant (TD) vs. postural instability gait disorder (PIGD) PD 
patients, and observed that PIGD phenotype had a higher prevalence of NMS and worse QOL 
than TD phenotype. These studies had one or more of the following shortcomings: they used 
only the partial aspects of PD (for example, using only motor aspects like speech or movement 
or non-motor aspects like the difficulty in olfaction) and did not make use of broad spectrum of 
symptoms in PD (both motor and non-motor); their sample size was limited; the accuracy of 
detecting PD was low; it required special hardware, sensors and sophisticated techniques for 
acquiring the data like the speech and movement data which makes their implementation costly 
and difficult; and/or they used expensive methods involving SPECT scanning. In our previous 
work [26], we used a combination of non-motor features of olfactory loss and Rapid Eye 
Movement sleep Behavior Disorder, along with other relevant biomarkers of Cerebrospinal fluid 
(CSF) measurements and SPECT imaging markers to develop predictive models for detecting 
early PD. 
Previous studies based on Patient Questionnaires (PQ) for PD have shown that the questionnaire 
features capture significant amount of information that helps in diagnosis [27-30]. The 
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) [31] is a 
widely used rating scale evaluating both motor as well as non-motor aspects of PD, and 
estimating its severity and progression. MDS-UPDRS consists of 4 parts and among which a 
portion of Part I (Parts IB, hereafter) and Part II, containing a total of 20 questions, is in the form 
of a patient questionnaire. Part IB assesses the non-motor aspects of daily living and Part II 
assess the motor aspects of daily living. Studies [31-34] have validated these parts and have 
observed that they provide a relevant estimate of PD symptoms. The Hoehn and Yahr (HY) scale 
is another widely used scale for assessing PD stage [35]. This scale provides an overall 
assessment of severity through staging. The progression of PD usually starts from unilateral 
(Stage 1), to bilateral without balance difficulties (Stage 2), followed by the presence of postural 
instability (Stage 3), to loss of physical independence (Stage 4), and being wheel-chair or bed-
bound unless aided (Stage 5). The HY scale has also been used to categorize PD as early stage 
(Stages 1 and 2), moderate stage (Stage 3) and late stage (Stages 4 and 5). Studies have shown 
that the PD stage has a significant correlation with quality of life measures and the UPDRS [36]. 
We have used the data from healthy normals and PD subjects who are in their early stages in our 
analysis. Developing predictive models that can perform classification or compute the likelihood 
of PD using patient questionnaire features is the approach that we carry out in this paper. There 
have been attempts to relate UPDRS (previous version of MDS-UPDRS) and the severity of PD 
through estimating the HY stage [37-39]. Scanlon et al. [37, 38] propose formulas to obtain HY 
stages from UPDRS Part III scores. Tsanas et al. [39] optimize this formula by refining its 
parameters using genetic algorithm (GA). However, these studies do not carry out predictive 
modelling and their formula was based on intuitive rules, and furthermore, Part III of MDS-
UPDRS which they used requires an expert PD clinician for rating.  
There are multiple advantages of using PQ features from MDS-UPDRS: a) it is simple to 
understand [31], they are easy to administer and can be administered even by primary physicians 
who are not PD experts , it is cheap and does not involve any invasive procedures; b) they have 
been extensively tested and validated in patient groups, and are observed to reflect an effective 
and relevant estimate of broad spectrum of symptoms in PD [31-34]; c) subjects can fill the 
questionnaire themselves. Studies based on PQ parts of UPDRS [40] (MDS-UPDRS is the 
updated version of UPDRS) show that PD patient self-assessment and caregiver evaluation of the 
patient's disability showed close concordance with the neurologist's ratings, and that they are a 
reliable and valid outcome measure [41, 42]; d) it assesses both non-motor (Part-IB) and motor 
(Part-II) features of PD [31].  
In this paper, we use the PQ parts (Parts IB and II) of MDS-UPDRS [31]) along with 
demographic information to classify PD patients from healthy normal using logistic regression, 
random forests, boosted trees and support vector machine (SVM). 
2. Materials and Methods 
2.1. Dataset details 
The data used for the study was from the Parkinson’s Progression Markers Initiative (PPMI) 
database (www.ppmi-info.org/data). For up-to-date information on the study, please visit 
www.ppmi-info.org. PPMI [43] is a landmark, large-scale, observational and multi-center study 
that recruits early-untreated PD patients along with age- and gender-matched healthy normal 
subjects, to identify progression biomarkers in PD.  
We have used the PQ portion of the MDS-UPDRS for the analysis. The complete MDS-UPDRS 
is freely available online at https://www.movementdisorders.org/MDS-Files1/PDFs/Rating-
Scales/MDS-UPDRS_English_FINAL.pdf. And the research article [31] providing more details 
on MDS-UPDRS can be found at http://onlinelibrary.wiley.com/doi/10.1002/mds.22340/pdf. 
The PQ parts of the MDS-UPDRS consisting of a total of 7 (in Part IB) + 13 (in Part II) = 20 
evaluations along with age and gender information, making a total of 22 features, are used as the 
feature set in this study. Each evaluation is answered based on its severity (0 – normal; 1 – slight; 
2 – mild; 3 – moderate; 4 – severe). The evaluations in Part IB are the following:  
1. Sleep Problems, 2. Daytime Sleepiness, 3. Pain and other sensations, 4. Urinary 
Problems, 5. Constipation problems, 6. Light Headedness on standing, 7. Fatigue.  
The evaluations in Part II are the following:  
8. Speech, 9. Saliva and Drooling, 10. Chewing and Swallowing, 11. Eating tasks, 12. 
Dressing, 13. Hygiene, 14. Handwriting, 15. Doing Hobbies and other activities, 16. 
Turning in bed, 17. Tremor, 18. Getting out of bed/car/deep chair, 19. Walking and balance, 
20. Freezing.  
PPMI is a longitudinal study where both PD and healthy subjects undergo a comprehensive 
longitudinal schedule of assessments [43]. Evaluations occur at screening/baseline and at 3 
month intervals during the first year of participation and then every 6 months thereafter for the 
next four years and it is followed by yearly assessment thereafter. The dataset contained 
observations for close to 7 years (July 2010 to April 2017). Average number of follow up visits 
for healthy normal is 5.06 and for PD is 9.92. The dataset consisted of a total of 5704 
observations with 1002 samples from 198 healthy normal subjects, and 4702 samples from 474 
early PD [44] (Hoehn and Yahr stage 1 or 2 with mean as 1.62) patients. The PQ was filled 
either by the patient / caregiver / patient and caregiver combined. Table 1 shows the distribution 
for each category. It is observed that around 99% of the healthy normal subjects and 95% early 
PD subjects put the ratings themselves.  
Table 1: Distribution of how the PQ was filled 
 N(%) 
Healthy Normal Early PD 
Patient 994 (99.20%) 4475 (95.17%) 
Caregiver 6 (0.60%) 8 (0.17%) 
Patient and Caregiver combined 2 (0.20%) 219 (4.66%) 
Total 1002 4702 
 
Figure 1(a) shows the stacked bar charts depicting the severity of features for normal and Figure 
1(b) for early PD groups. It can be observed that all the features are getting affected in PD. 
Figure 2 shows the quantitative measure for the affected features. The quantification is done by 
computing the difference of percentages of samples showing normal behavior for each feature 
between Healthy Normal and Early PD. From this plot, we can observe that tremor, handwriting 
and dressing are the most affected features. As the PPMI study mainly recruits early and 
untreated PD subjects, their symptoms or the features (in the questionnaire) are subtle. For 
instance, the number of early PD observations showing no sign of tremor (which is the most 
obvious symptom in PD, feature no. 17) is 715 which is around 15% of total early PD 
observations in the study. Figure 3 shows the percentage of PD samples showing normal 
behavior for each feature. From this plot, it is clear that majority of the observations from the PD 
group showed severity in tremor, and only few observations showed severity in the Freezing 
symptom. 
2.2. Data Partitioning 
As PPMI is a longitudinal study where subjects are followed up, measurements are taken at 
different time points for each subject. In this study, along with record-wise cross-validation, we 
also carry out subject-wise cross-validation. In subject-wise cross-validation, the data is 
partitioned in a 10-fold cross-validation set up such that for each fold about 90% subjects, i.e. 
data from 605 subjects (178 Normal + 427 Early PD) were used for training and rest about 10% 
subjects, i.e., data from 67 subjects (20 Normal + 47 Early PD) were used for testing, and this 
cross-validation process is repeated 100 times. In record-wise cross-validation, the data is 
partitioned in a 10-fold cross-validation set up such that for each fold 90% of the whole data, i.e., 
5134 observations were used for training and rest 10%, i.e., 570 observations were used for 
testing, and this cross-validation process is repeated 100 times The partitioning of the dataset 
into training and testing sets is carried out in a stratified manner, i.e., in such a way that both sets 
are mutually exclusive and have roughly the same class proportions as in the set of class labels. 
The average measure from the 100 cross-validation runs is taken to get an unbiased estimate of 
performance measures used which are accuracy, sensitivity, specificity and area under the ROC 
curve (AUC).  
 
(a) 
 (b) 
Fig. 1. Stacked bar charts showing the severity of PQ features in the MDS-UPDRS for (a) 
Healthy Normal, and (b) Early PD groups. X- and Y-axes represent the features (abbreviated) and 
the number of observations, respectively. The features from Part I are indicated by P1 and those 
from Part II are indicated by P2. The severity is indicated by color-coding as indicated by the 
legend in the figure. The plots show that all features are getting affected in PD.  
 Fig. 2. Plot of difference of percentages of observations showing normal behavior for each 
feature between the Normal and PD groups. It is observed that tremor (P2_TRMR), handwriting 
(P2_HWRT) and dressing (P2_DRESS) were the most affected features. 
 
Fig. 3. Plot of percentage of samples from PD group who show normal behavior for each feature. 
2.3 Feature selection techniques used 
Feature selection is a necessary step before predictive modelling when there is redundancy 
between the features. It is also necessary as decreased set of features reduces the size of the 
problem which makes the training time lesser, and there is lesser chance of overfitting. To carry 
out feature selection, we use the techniques as mentioned below: 
2.3.1 Wilcoxon rank sum test 
It is a filter based method where the selection of features is carried out based on (univariate) 
statistical tests. In this study, we use the Wilcoxon rank sum test for analyzing the significance of 
features. The Wilcoxon rank sum test is a nonparametric test for two populations to test for the 
equality of the population medians [45]. We use this test, instead of the t-test as most of the 
features do not show a normal distribution. For illustration, the histograms of the first four 
features are as shown below in Figure 4. 
 Fig. 4. Histograms of the first four features. We can clearly observe that the histograms are 
highly skewed. This is because the PD subjects in the study were all in their early stages where 
the symptoms were less severe.  
2.3.2 LASSO based feature selection 
Least Absolute Shrinkage and Selection Operator (LASSO) is a regularization technique which 
applies a shrinking process where it penalizes the coefficients of the regression variables 
shrinking some of them to zero [46]. During this process, the variables that still have a non-zero 
coefficient are selected for subsequent prediction modelling. 
2.3.3 PCA 
PCA is a dimensionality reduction technique used to decompose a multivariate dataset to a set of 
orthogonal components. It converts the dataset of possibly correlated variables into a set of 
values of linearly uncorrelated variables called principal components. These components are 
obtained from the eigenvectors of the covariance matrix, and give directions in which the data 
have maximal variance [47]. In that way, the first principal component has the largest possible 
variance. Features are selected such that the total percentage of variance explained by selected 
components is not less than 99%. 
2.4. Predictive modelling for distinguishing early PD from healthy normal 
The input data can be represented as 𝒙𝑖 = [𝑥𝑖1, 𝑥𝑖2, … , 𝑥𝑖 𝑘] ; 𝑖 = 1, … , 𝑛; k is number of features, 
k = 22, and n is number of observations, n=5704; and the output class as 𝑦 ∈ {0, 1} where 0 and 
1 represent normal and early PD, respectively. The goal of the predictive model is to compute 
𝑝(𝑦|𝒙𝑖) which is the output class (or probability of PD) for an observation 𝒙𝑖 . 
For classification, we use conventional techniques such as logistic regression [47] which is 
among the most popular techniques used in biomedical, as well as more recent techniques such 
as random forests [48, 49], boosted trees [50] and SVM [51] that are becoming very popular in 
biomedicine [49, 52]. We use statistics toolbox in MATLAB to carry out classification using 
logistic regression, random forests and boosted trees, and LIBSVM [53] library for SVM 
modelling. More detailed description of these techniques is given in the Supplementary file. 
2.5. Variable importance 
Along with classification, Random forests technique was also used to evaluate feature 
importance [48]. During bagging (which is selecting samples with replacement) process as used 
in Random forests, it leaves out about 37% of the examples for each tree. It means that each tree 
is trained using only about 63% of the data on average. These left out examples are called out-of 
bag (OOB) samples. The first step in computing the variable importance is to fit a Random 
forests model to the data. Compute the OOB error which is the misclassification rate for OOB 
observations in the data. After this, to estimate the importance of the j
th
 feature, the values of the 
j
th
 feature are randomly permuted (shuffled) in the training data and the OOB error is again 
computed on this perturbed data set. The importance score for the feature is computed by 
averaging the difference in OOB error before and after the permutation. The score is normalized 
by the standard deviation of these differences. Features with higher scores are ranked higher. 
3. Results 
3.1. Feature Selection 
For the analysis, a 10-fold nested cross-validation based approach was carried out where the 
feature selection and parameter tuning happens in the inner fold and evaluation happens in an 
independent set (or fold).  
3.1.1 Features Selected from Wilcoxon rank sum test 
The features are statistically tested using two-sided Wilcoxon rank sum test and 21of them were 
observed to be statistically significant in all folds (p-value << 0.05). Age was statistically 
insignificant as both the groups (Healthy normal and Early PD) were age matched. Table 2 
below shows the results of this statistical testing. All features, except age, were included in the 
subsequent prediction modelling. 
 
 
 
 
Table 2: Statistical testing of features 
SNo Features Abbrv. HC 
(mean±SD) 
PD 
(mean±SD) 
z-stat p-val 
1  Sleep Problems P1_SLPN 0.77±0.97 1.03±1.09 -6.7863 1.15E-11 
2 Daytime Sleepiness P1_SLPD 0.57±0.75 0.95±0.86 -12.758 2.81E-37 
3 Pain and other sensations P1_PAIN 0.49±0.75 0.8±0.88 -11.681 1.60E-31 
4 Urinary problems P1_URIN 0.33±0.63 0.75±0.86 -15.911 5.35E-57 
5 Constipation problems P1_CNST 0.13±0.4 0.55±0.73 -18.602 3.10E-77 
6 Light Headedness on 
standing 
P1_LTHD 0.11±0.34 0.39±0.67 -13.581 5.20E-42 
7 Fatigue P1_FATG 0.35±0.6 0.77±0.85 -15.625 4.89E-55 
8 Speech P2_SPCH 0.03±0.21 0.61±0.82 -23.605 3.45E-123 
9 Saliva and Drooling P2_SALV 0.09±0.39 0.73±1.03 -20.839 1.91E-96 
10 Chewing and Swallowing P2_SWAL 0.02±0.16 0.22±0.49 -13.81 2.22E-43 
11 Eating tasks P2_EAT 0.01±0.08 0.48±0.63 -24.15 7.54E-129 
12 Dressing P2_DRES 0.02±0.17 0.59±0.66 -27.345 1.22E-164 
13 Hygiene P2_HYGN 0±0.05 0.35±0.5 -21.677 3.40E-104 
14 Handwriting P2_HWRT 0.08±0.34 1.05±0.96 -32.772 1.49E-235 
15 Doing Hobbies and other 
activities 
P2_HOBB 0.03±0.23 0.62±0.76 -25.683 1.83E-145 
16 Turning in bed P2_TURN 0.04±0.19 0.41±0.55 -20.965 1.37E-97 
17 Tremor P2_TRMR 0.06±0.23 1.17±0.74 -43.366 0 
18 Getting out of bed/car/deep 
chair 
P2_RISE 0.08±0.27 0.59±0.68 -24.216 1.50E-129 
19 Walking and balance P2_WALK 0.07±0.33 0.52±0.61 -24.124 1.39E-128 
20 Freezing P2_FREZ 0±0.05 0.09±0.34 -9.0586 1.32E-19 
21 Gender GENDER 0.62±0.49 0.66±0.47 -2.3313 0.01974 
22 Age AGE 66.42±11.09 66.61±9.69 0.09147 0.927122 
p-value shows statistical significance. Abbrv is the abbreviation.  
 
 
3.1.2. Features selected from LASSO technique 
A 10-fold cross-validated lasso regularization of a logistic regression model is created for feature 
selection. The features having non-zero coefficients were selected and the rest were discarded in 
each fold of the nested cross-validation. 
3.1.3. Features selected from PCA 
PCA decorrelates the features and finds a new representation from the existing features. Here, we 
have selected those many principal components which retain 99% of the total variance. Figure 5 
as shown below visualizes the transformed representation using the first three features. The plot 
shows the largest variability along the first principal component axis. The second principal 
component axis has the second largest variability, which is significantly smaller than the 
variability along the first principal component axis. Similarly for the third principal component 
axis. 
 
 
Fig. 5. Visualization of the first three transformed features using PCA 
3.2 Hyperparameter selection 
Hyper parameter optimization for the methods of Boosted Trees, Random Forest and SVM were 
carried out using Bayesian optimization [54] in a nested cross-validation framework. The 
Bayesian optimization algorithm attempts to minimize a scalar objective function f(x) for x in a 
bounded domain. For Boosted trees and SVM, the optimization function was 10-fold cross 
validation error and for Random forest, the function was the out-of-bag error. 
3.3 Performance measures of the classifiers used 
The performance metrics obtained for the classifiers used is shown in Table 3 below. It is 
observed that all the classifiers performed with high accuracy and high AUC. To statistically 
compare the performances from the classifiers, multiple comparison tests were carried out [26, 
55]. In this procedure, one-way ANOVA followed by post hoc tests using Tukey-Kramer method 
were carried out for multiple comparison analysis to determine which pairs of means are 
significant and which are not. The figure below (Fig. 6) shows the plots obtained from these 
tests. In each plot, the mean of the classifier performance measure is represented by a circle 
symbol and an interval (95% confidence interval) around the symbol. Two means are 
significantly different if their intervals are disjoint, and are not significantly different if their 
intervals overlap. In the plots below, solid blue line represent the best performing methods and 
solid red line represent the groups whose means were significantly  different from the best 
performing method. From these plots, we observe that SVMs were always gave comparable 
performance with the best performing methods.  
 
 
Table 3. Performance measures of the classifiers for the subject-wise and record-wise cases 
(A) Subject-wise nested cross validation 
 
Wilcoxon rank sum test 
 
Boosting trees Random forests Logistic regression SVM 
 
95% CI 95% CI 95% CI 95% CI 
Accuracy 93.88% 96.59% 94.18% 96.57% 93.90% 96.49% 94.30% 96.61% 
Sensitivity 95.29% 97.61% 96.56% 98.27% 96.26% 98.72% 95.95% 97.99% 
Specificity 83.54% 95.95% 79.22% 92.63% 81.50% 89.22% 82.63% 94.41% 
AUC 96.77% 98.88% 96.42% 98.76% 96.94% 98.67% 96.06% 98.55% 
 
Feature selection via LASSO 
 
Boosting trees Random forests Logistic regression SVM 
Accuracy 94.19% 96.79% 94.60% 97.22% 94.07% 96.53% 94.17% 96.55% 
Sensitivity 95.38% 97.66% 96.83% 98.64% 96.39% 98.78% 95.81% 97.95% 
Specificity 85.11% 96.63% 80.71% 94.36% 81.82% 89.21% 82.40% 94.45% 
AUC 96.71% 98.80% 96.10% 98.65% 96.91% 98.71% 96.11% 98.62% 
 
Feature selection via PCA 
 
Boosting trees Random forests Logistic regression SVM 
Accuracy 93.81% 96.39% 92.99% 95.64% 93.97% 96.47% 94.23% 96.77% 
Sensitivity 96.45% 98.36% 96.77% 99.09% 96.38% 98.82% 95.86% 98.14% 
Specificity 77.55% 91.21% 70.02% 84.66% 81.50% 88.79% 82.55% 94.67% 
AUC 96.24% 98.39% 95.51% 97.82% 97.00% 98.65% 96.17% 98.75% 
(B) Record-wise nested cross validation 
 
Wilcoxon rank sum test 
 
Boosting trees Random forests Logistic regression SVM 
 
95% CI 95% CI 95% CI 95% CI 
Accuracy 94.62% 96.09% 95.56% 96.66% 94.55% 96.33% 95.64% 96.96% 
Sensitivity 95.76% 97.52% 97.04% 98.41% 97.24% 98.05% 96.56% 98.17% 
Specificity 87.40% 91.23% 86.17% 90.87% 82.18% 89.58% 89.04% 93.58% 
AUC 97.61% 98.48% 98.04% 98.77% 97.53% 98.44% 98.09% 98.82% 
 
Feature selection via LASSO 
 
Boosting trees Random forests Logistic regression SVM 
Accuracy 95.05% 96.40% 96.20% 97.14% 94.72% 96.16% 95.71% 96.96% 
Sensitivity 96.07% 97.63% 97.55% 98.58% 97.29% 98.12% 96.61% 98.15% 
Specificity 88.90% 91.94% 88.31% 91.92% 82.50% 88.73% 89.27% 93.56% 
AUC 97.72% 98.59% 98.59% 99.29% 97.63% 98.51% 98.05% 98.86% 
 
Feature selection via PCA 
 
Boosting trees Random forests Logistic regression SVM 
Accuracy 94.83% 96.05% 94.83% 96.19% 94.68% 96.20% 95.57% 96.92% 
Sensitivity 96.79% 98.23% 97.85% 99.30% 97.34% 98.03% 96.68% 98.17% 
Specificity 83.56% 87.89% 78.15% 84.12% 82.27% 89.21% 88.54% 92.88% 
AUC 97.44% 98.45% 97.83% 98.80% 97.56% 98.44% 97.87% 98.77% 
*CI represents confidence interval 
   
 
 
(a)  Subject-wise case 
  
  
(b)  Record-wise case 
Fig. 6. Statistical comparison of the classifier performance measures of Accuracy, Sensitivity, 
Specificity, and Area under ROC (AUC) using multiple comparison tests. BT, RF, LR, and SVM 
represent Boosted Trees, Random Forests, Logistic Regression, and Support Vector Machine, 
respectively. Wil, lasso, and pca represent the feature selection techniques used which are 
Wilcoxon rank sum test, LASSO based, and PCA based feature selection. 
3.4 Comparison of machine learning models with the patient questionnaire scores 
In clinical setting, the total score is an important factor considered. However, there is no 
threshold that is reported that can be used to distinguish between PD and healthy normal. To 
compare the performance of questionnaire alone with the machine learning approaches, we have 
taken the total score of the questionnaire and then plotted the AUCs. The below figure (Fig. 7) 
shows the AUCs for different approaches, and we can clearly observe that the machine learning 
approaches are performing much better here. 
 Fig. 7. Plot of Area under ROC curve (AUC) for questionnaire only along with the machine 
learning approaches. 
 
 
Fig. 8. Plot of feature importance scores from Random forests. It is observed that the features of tremor 
(P2_TRMR) and handwriting (P2_HWRT) were more important, and freezing (P2_FREZ) was the least 
important feature. This pattern is similar to what we observe in Fig 2. It is interesting to note that age was 
showing higher importance as compared to gender. 
3.5. Logistic regression model 
The performance metrics obtained for logistic regression are shown in Table 3 and it is observed 
to perform with high accuracy and area under the ROC curve (AUC). The equation 𝑝 𝑦 =
𝑃𝐷 =  (1 + exp−(𝑓(𝑥)))−1 is the logistic model developed where 𝑝 𝑦 = 𝑃𝐷  represents the 
likelihood of having PD. The logistic model developed using the full data is as given in equation 
(1) as shown below. 
𝑓 𝑥 =  4.3677 ∗  𝑇𝑟𝑒𝑚𝑜𝑟 +   2.2193 ∗  𝐸𝑎𝑡𝑖𝑛𝑔 𝑡𝑎𝑠𝑘𝑠 +   2.1455 ∗  𝐻𝑦𝑔𝑖𝑒𝑛𝑒 
+   1.6894 ∗  𝑆𝑝𝑒𝑒𝑐𝑕 +   1.4171 ∗  𝐷𝑟𝑒𝑠𝑠𝑖𝑛𝑔 +   1.1776 ∗  𝐹𝑟𝑒𝑒𝑧𝑖𝑛𝑔 
+   1.1211 ∗  𝐻𝑎𝑛𝑑𝑤𝑟𝑖𝑡𝑖𝑛𝑔 +   1.0682 ∗  𝐶𝑜𝑛𝑠𝑡𝑖𝑝𝑎𝑡𝑖𝑜𝑛 𝑝𝑟𝑜𝑏𝑙𝑒𝑚𝑠 
+   0.90309 ∗  𝐶𝑕𝑒𝑤𝑖𝑛𝑔 𝑎𝑛𝑑 𝑆𝑤𝑎𝑙𝑙𝑜𝑤𝑖𝑛𝑔 
+  0.7519 ∗  𝑆𝑎𝑙𝑖𝑣𝑎 𝑎𝑛𝑑 𝐷𝑟𝑜𝑜𝑙𝑖𝑛𝑔 
+   0.72112 ∗  𝐺𝑒𝑡𝑡𝑖𝑛𝑔 𝑜𝑢𝑡 𝑜𝑓 𝑏𝑒𝑑/𝑐𝑎𝑟/𝑑𝑒𝑒𝑝 𝑐𝑕𝑎𝑖𝑟  
+   0.70782 ∗  𝑇𝑢𝑟𝑛𝑖𝑛𝑔 𝑖𝑛 𝑏𝑒𝑑                                                                              1 
+   0.57116 ∗  𝐷𝑜𝑖𝑛𝑔 𝐻𝑜𝑏𝑏𝑖𝑒𝑠 𝑎𝑛𝑑 𝑜𝑡𝑕𝑒𝑟 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑖𝑒𝑠 
+   0.3455 ∗  𝑊𝑎𝑙𝑘𝑖𝑛𝑔 𝑎𝑛𝑑 𝑏𝑎𝑙𝑎𝑛𝑐𝑒 
+   0.16622 ∗  𝐿𝑖𝑔𝑕𝑡 𝐻𝑒𝑎𝑑𝑒𝑑𝑛𝑒𝑠𝑠 𝑜𝑛 𝑠𝑡𝑎𝑛𝑑𝑖𝑛𝑔 
+   0.026638 ∗  𝐷𝑎𝑦𝑡𝑖𝑚𝑒 𝑆𝑙𝑒𝑒𝑝𝑖𝑛𝑒𝑠𝑠 +   0.022716 ∗  𝑈𝑟𝑖𝑛𝑎𝑟𝑦 𝑝𝑟𝑜𝑏𝑙𝑒𝑚𝑠 
−   0.031956 ∗  𝐴𝑔𝑒 −   0.33983 ∗  𝑃𝑎𝑖𝑛 𝑎𝑛𝑑 𝑜𝑡𝑕𝑒𝑟 𝑠𝑒𝑛𝑠𝑎𝑡𝑖𝑜𝑛𝑠 
−   0.41561 ∗  𝐺𝑒𝑛𝑑𝑒𝑟 −   0.41803 ∗   𝑆𝑙𝑒𝑒𝑝 𝑃𝑟𝑜𝑏𝑙𝑒𝑚𝑠 
−   0.49868 ∗  𝐹𝑎𝑡𝑖𝑔𝑢𝑒 +  0.54813 
As per this model, the logarithm of odds of an observation to be early PD is positively related to 
17 predictors and negatively related to the 5 predictors. It is to be noted that these 5 predictors 
are negatively related only in the multivariate model and not in the univariate model. The model 
chi-square value is 3875.3 with p-value << 0.05 indicating that the model fits significantly better 
than a null model (a model with no predictors). The Cox and Snell R
2
, and Nagelkerke R
2
 are 
obtained as 0.49 and 0.82, respectively, which indicate that the relationship between the outcome 
and predictors is strong, and that the model is useful in risk prediction. These values indicate that 
the logistic model was well fit to the data. 
4. Discussion 
4.1 Note on final models 
The main focus of the study was to develop predictive models using patient questionnaire in 
classifying early PD from healthy normal. Different machine learning techniques were used and 
compared. All the classifiers performed well and produced comparable performance. Table 3 
shows the performance measures obtained for classifiers for subject-wise and record-wise case 
with feature selection using Wilcoxon rank sum test, LASSO and PCA.  
Among all the techniques used, logistic regression is capable of giving the likelihood of PD in 
terms of a probability. The logistic model using full data is given in Section 3.2. In similar 
fashion, the Boosted trees, Random forests and SVM models can be built using the full data. The 
logistic model showed a statistically significant goodness-of-fit measure as indicated by the R
2
 
value. This indicates a good fit to the data, and hence is useful as a predictive model. These 
prediction models show the potential to aid in the initial evaluation of a subject, which can be 
followed with clinical evaluation by an PD expert and/or SPECT imaging that has the potential 
to enhance and validate the diagnostic decision significantly, and thereby can be used a 
secondary evaluation measure (as it is very expensive).  
Table 4 shows a comparison of our study with other related works in developing machine 
learning based prediction models for PD detection. The contributions (advantages) of this study 
can be summarised as follows: 
a) We improve the works of [32-34] by providing a different perspective of using PQ to 
develop prediction models for the early PD vs. normal classification. 
b) It does not need any special hardware (like in the speech recording or motion recording 
works) for data acquisition. Instead, it uses a cheap and simple patient questionnaire that 
can be used even by primary physicians who are not experts in PD. 
c) The sample size used is largest as compared to related works in PD detection [3-13, 21-
23].  
d) The classification accuracy is comparable with related works in PD detection [3-13, 21-
23].  
Table 4: Comparison with related works 
Study Type of data used No. of subjects Classifier used Accuracy/
AUC  
[3] Speech 23 PD, 8 N neural network (NN) 92.9% 
[4] Speech 23 PD, 8 N parallel feed-forward NN 91.20% 
[5] Speech 23 PD, 8 N fuzzy k-nearest neighbor 96.07%. 
[6] Speech 33 PD, 10 N SVM 98.6% 
[7] Speech 20 PD, 20 N SVM 77.50% 
[8] Motion video 7 PD, 7 N linear discriminant analysis and 
minimum distance classifier 
95.49% 
[9] Force tracking 30 PD, 30 N SVM 85% 
[10] * SPECT scan 41 PS, 39 N SVM 95% 
[11] * SPECT scan 100 PS, 108 N SVM 96.81%  
[12] SPECT scan 369 PD, 179 N SVM 96.14% 
[13] Smell identification 193 PD, 157 N Logistic regression 88.4% 
[21] Demographic, imaging, 
genetics and clinical 
263 PD + 123 N + 
37 SWEDD** 
Adboost 98% 
[23] Motor, non-motor and 
imaging data 
189 PD + 415 N + 
63 SWEDD 
Probabilistic neural network >98% 
[22] Genetic, non-motor and 
demographic data 
367 PD + 165 N Logistic regression >92% 
Our 
study 
Patient questionnaire 446 PD, 180 N Logistic Regression, Random 
forests, Boosted trees, SVM 
>95% 
PD and N represent Parkinson's disease and healthy normal, respectively. Unlike other approaches, which 
use sophisticated hardware for signal acquisition or are expensive or use only partial aspects of PD for 
evaluation, our approach uses PQ which is simple to understand, easy to administer and complete, cheap, 
extensively tested and evaluates a broad spectrum of features (both motor and non-motor) of PD. The 
classifier which produced the highest accuracy is shown in 'Classifier used' column. The ‘Accuracy/AUC’ 
columns represents either the accuracy or AUC as few studies reported AUC in place of accuracy. 
* studies involve Parkinsonism (PS, which is a group of disorders that present PD-like symptoms and PD 
is one among them) subjects. 
**SWEDD stands for Scans Without Evidence of Dopaminergic Deficit. These are the subjects who show 
PD symptoms but show normal in SPECT scanning, 
4.2. A note on misclassified instances 
To illustrate the misclassified instances, the figures 9 and 10 as given below show the stacked 
bar charts for the misclassified instances from the Random forests classifier for the subject-wise 
and record-wise cases, respectively. These plots show the collective misclassified instances from 
the 100 runs of 10-fold cross-validations. We can see that the pattern for misclassified healthy 
normals is way different from the severity pattern that we observe in Figure 1. We can clearly 
observe from the plots that those healthy normals who showed a severity pattern close to that of 
early PD were misclassified as early PD. And for the early PD case, as the training data involved 
few healthy normal instances which showed a severity pattern close to that of early PD, the 
classifier learned to these instances and misclassified few early PD instances as healthy normal. 
Similar patterns were observed with other classifiers as well. These misclassifications can be 
reduced by incorporating other features such as inputs from PD experts and/or neuroimaging can 
increase the performance to a great extent.  
 (a) 
 
(b) 
 
 (c) 
 
(d) 
Fig. 9.The stacked bar charts for misclassified instances from the Random forests classifier for 
for healthy normal and early PD. 
4.3. Correlation study of features 
Striatal Binding Ratios (SBRs) are clinically used quantitative measurements computed from 
SPECT imaging for detecting PD. We computed the Spearman correlation coefficient of all 
features used in the study along with the SBR features with the Hoehn and Yahr (HY) stage of 
the subjects. The plot of the correlation coefficients is shown in Figure 10 below. It is very 
encouraging to observe that the 20 features from the PQ used in the study showed significant 
correlations, although lesser than the SBR values, indicating its usefulness in PD detection. All 
correlation values were statistically significant, except for the gender feature indicating that 
gender plays not much role in the severity of PD. Dressing, Handwriting, Getting out of 
bed/car/deep chair and Tremor were the ones showing higher correlation with HY.  
 
Fig. 10. Correlation study of features along with the clinically used striatal binding ratio (SBR) features. 
The first 22 features are the ones used in the study (shown in blue). The last 4 features (shown in green) 
correspond to the SBR ones that are right caudate, left caudate, right putamen and left putamen SBR. The 
PQ features showed significant correlations although lesser than the clinically used SBR ones, indicating 
its usefulness in PD detection. Dressing (P2_DRESS), Handwriting (P2_HWRT), Getting out of 
bed/car/deep chair (P2_RISE) and Tremor (P2_TRMR) were the ones showing higher correlation with 
HY. 
Generally the clinician looks at the total score of the questionnaire for evaluating a subject. The 
total of the questionnaire features gave a higher correlation of 0.54 with the HY stage. 
The correlation of the sum of MDS-UPDRS part III with HY was observed to be 0.76 which is 
higher as compared to the correlation for the sum of the questionnaire. Incorporation of part III 
could enhance the performance of the models which is a further extension of the present study. 
4.4. Note on screening instrument for PD 
In the present paper, the prediction models developed could aid a primary physician, who is not a 
PD expert, to detect possible case of PD and subsequently he/she may refer the subject to an PD 
expert for confirmatory neurological examination and other expensive tests such as the SPECT 
scan which provides a specificity as high as 100% [56]. Screening for PD is a clinical need as 
there exist no approaches as of now that can be used as a screening tool. Developing a screening 
tool possibly from tool like a patient questionnaire for PD is a long term goal and the presented 
approaches are like first steps towards that long term goal. The requirements for any screening 
instrument that can be used for population-wide studies are that it must be sensitive, specific, 
inexpensive, and non-invasive. An effective screening instrument/tool can serve the following: 
i. To identify undiagnosed and preclinical stage PD to initiate early management and 
therapeutic intervention.  
ii. To carry out prevalence studies for evaluating the burden of PD, especially in developing 
countries where access to health care is limited, and thereby helping policy makers to 
estimate health care costs and allocate resources more efficiently. 
iii. It can aid in clinical trial studies such as the PPMI for recruiting new subjects. 
4.5. Limitations and future work 
A limitation of this study is that the binary classification (early PD/healthy normal) does not 
provide a differential diagnosis (i.e., diagnosis of PD from other forms of Parkinsonism which 
show PD-like symptoms such as multiple system atrophy, progressive supra-nuclear palsy and 
corticobasal degeneration), but it is a promising first step toward that long-term goal. 
Incorporation of data for these neurodisorders is another possible extension of the present study. 
Furthermore, sensitivity from a PQ would be much lower as compared to SPECT scans. But our 
study mainly focused on PQ due to its ease of use and cost-effectiveness. Studies have 
established that PD patient self-assessment or caregiver evaluation of a patient's disability (based 
on patient questionnaire) show very close concordance with the neurologist's ratings, and that 
they are reliable and valid outcome measures [41, 42]. However, a comparison with neurologist's 
rating, which we have not carried out in this study, can further add value to the work. It is to be 
noted that a study by Martinez-Martin et al. [41] observed that a doctor's rating from a question-
and-answer session may bias patient's answers, or underestimate its severity. A self-administered 
patient questionnaire does not suffer from these biases, and as such, may be a better tool to 
collect such data.  
This proposed approach is an alternative way of joining the items of an existing questionnaire 
through machine learning. However, it is to be noted that the PPMI group in their research article 
had acknowledged that the study recruitment is a major challenge for the PPMI due to the 
difficulty in identifying early-untreated PD subjects. The group, working closely with the 
Michael J Fox Foundation, had developed a template which they use for recruiting new subjects. 
The patients have been clinically diagnosed as PD and they form the ground truth or target 
variable for our study, which enables us to develop predictive models using it. And these models 
could potentially be used as a clinical aid as well for identifying subjects for clinical trials. 
Application of this approach for detecting prodromal phase is interesting which is a worthy 
candidate for future work. 
Furthermore, deep learning is an area of machine learning that is increasingly being used in 
biomedicine. It involves representation-learning methods composing of multiple processing 
layers to learn representations of data with multiple levels of abstraction. These methods have 
dramatically improved the state-of-the-art in many supervised classification tasks [57]. These 
techniques could be applied for generating more complex insights, but for that a substantial 
amount of data is necessary. Along with this, including sensor data, when it becomes available in 
the PPMI database, to the problem could further add value to the work. 
4.5.1. A note on the lack of correlations with subjective-objective data 
The items in the questionnaire data which is of subjective type had a weak to moderate 
correlations (0.10 – 0.38) with the Hoehn and Yahr (HY) stage as we can observe from Figure 
11. Although, these correlations were lower, the correlation for the sum of these 20 items came 
around 0.54 which is a reasonably stronger correlation as compared to individual features.  
The SBR data which is of objective type had moderate correlations (0.45 ‒ 0.56) with the HY 
stage. The total SBRs also had moderate correlations, but slightly higher, with the HY stage. A 
possible reason for the lower correlations could be that we had used only 3 categories for the HY 
which are normal, stage 0 and stage 1, rather than using the full spectrum of HY. Another reason 
could that the progression of the disease is a non-linear process and varies from person to person. 
However, a further study on the lack of these correlations is a promising future work. 
4.5.2 Few other recommendations 
Literature survey shows that there have been many studies using a variety of data such as 
imaging data, smell data, movement data, speech data, etc, but only few works focused on 
developing predictive models using patient questionnaire data. From our study, we demonstrate 
that effective machine learning models can be developed using the PQ data. In our analysis, we 
had used the PQ portion of the MDS-UPDRS. This work could be extended by including other 
patient questionnaires (or any other data) for Parkinson’s disease which might improve the 
performance of the models. Along with that neural network techniques could be used which are 
capable of learning refined representations from the data, and could possibly perform 
dimensionality reduction along with performance improvement. 
5. Conclusion 
Computer-aided detection or classification has the potential to reduce inevitable fallibilities and 
inherent diagnostic variabilities in healthcare, provide guidance and speed up decision-making. 
The seemingly vast and promising opportunities that machine learning will bring to healthcare 
will also advance precision medicine and disease management at the level of individual patients. 
Early detection of PD is an important step to understand the causes, develop better treatments 
and carry out effective early management of the disease. The importance of diagnostic tools 
stems from the fact that they can aid in the early detection of PD. In this study, we use the patient 
questionnaire parts of the widely used MDS-UPDRS to classify early PD cases from healthy 
normal, to develop prediction models using a variety of classifiers. We observe that these 
predictive models performed with high accuracy and AUC in distinguishing early PD cases from 
normal. We infer from the study that such diagnostic models might have the potential to be used 
as an aid in clinical setting by primary physicians when PD expert are not available, for detecting 
PD and also for identifying subjects for clinical trials. 
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